Head to head
KPV against Larazotide
Two peptides for the intestinal lining at opposite ends of the evidence. Larazotide reached a phase 3 that missed its endpoint and was terminated; KPV's record is preclinical models of gut inflammation.
Column A
KPVKPV (lysine-proline-valine, alpha-MSH fragment)
A small anti-inflammatory tripeptide derived from alpha-MSH studied for gut inflammation and skin, mostly in preclinical models.
Column B
LarazotideLarazotide Acetate (AT-1001)
An investigational gut-barrier peptide for celiac disease that reached Phase 3 but was terminated by the sponsor without a published result.
Side by side, on the facts we can check
| Attribute | KPV | Larazotide |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6 to recommend for compounding (July 2026); awaiting FDA rulemaking | Investigational; Phase 3 did not meet primary endpoint |
| Half-life | Short | Short (acts locally in the gut) |
| Molecular weight | 342.4 Da | ~732 Da |
| Mechanism | Enters cells and suppresses pro-inflammatory NF-kB signaling, reducing inflammatory cytokine production. | Antagonizes zonulin signaling to strengthen intestinal tight junctions and limit passage of gluten fragments across the gut lining. |
| Human studies cited | 0 | 3 |
| Legal status, US | Not approved; research use only | Investigational, not approved |
Frequently asked questions
What is the difference between KPV and Larazotide?
KPV: A small anti-inflammatory tripeptide derived from alpha-MSH studied for gut inflammation and skin, mostly in preclinical models. Larazotide: An investigational gut-barrier peptide for celiac disease that reached Phase 3 but was terminated by the sponsor without a published result.
Which has stronger research evidence, KPV or Larazotide?
This database does not grade compounds. It counts what was run in people: 0 of the 3 studies cited on the KPV profile were human work, against 3 of 3 for Larazotide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are KPV and Larazotide FDA-approved?
KPV: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6 to recommend for compounding (July 2026); awaiting FDA rulemaking. Larazotide: Investigational; Phase 3 did not meet primary endpoint.
Related posts
Blog articles that cover KPV or Larazotide, newest first.
- Healing & Recovery / Sep 8, 2026 / 8 minPeptides for Gut Health: BPC-157, KPV and Larazotide Ranked by Human Evidence
- Healing & Recovery / Sep 8, 2026 / 8 minGLOW vs KLOW vs Wolverine: What Is in Each Stack and What the Evidence Says, Ingredient by Ingredient
- Regulation / Sep 8, 2026 / 9 minFDA Peptide Status in 2026: The Category 2 Removals, the July Votes, and What Actually Changed
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.